AR047345A1 - Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes - Google Patents

Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes

Info

Publication number
AR047345A1
AR047345A1 ARP040104868A ARP040104868A AR047345A1 AR 047345 A1 AR047345 A1 AR 047345A1 AR P040104868 A ARP040104868 A AR P040104868A AR P040104868 A ARP040104868 A AR P040104868A AR 047345 A1 AR047345 A1 AR 047345A1
Authority
AR
Argentina
Prior art keywords
peptides
gdf8
epithopes
vaccine
neutralizing
Prior art date
Application number
ARP040104868A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34748944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047345(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of AR047345A1 publication Critical patent/AR047345A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ARP040104868A 2003-12-31 2004-12-22 Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes AR047345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53371903P 2003-12-31 2003-12-31

Publications (1)

Publication Number Publication Date
AR047345A1 true AR047345A1 (es) 2006-01-18

Family

ID=34748944

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104868A AR047345A1 (es) 2003-12-31 2004-12-22 Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes

Country Status (21)

Country Link
US (3) US7371726B2 (enExample)
EP (1) EP1699820A2 (enExample)
JP (2) JP2007535912A (enExample)
KR (1) KR20060120229A (enExample)
CN (1) CN1902221A (enExample)
AR (1) AR047345A1 (enExample)
AU (1) AU2004312411B8 (enExample)
BR (1) BRPI0418317A (enExample)
CA (1) CA2551877A1 (enExample)
EC (1) ECSP066683A (enExample)
IL (1) IL176494A0 (enExample)
MX (1) MXPA06007514A (enExample)
NO (1) NO20063478L (enExample)
NZ (1) NZ547593A (enExample)
PE (1) PE20051050A1 (enExample)
RU (1) RU2422460C2 (enExample)
SG (1) SG153874A1 (enExample)
TW (1) TWI357906B (enExample)
UA (1) UA93855C2 (enExample)
WO (1) WO2005066204A2 (enExample)
ZA (1) ZA200605227B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) * 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
US8460864B2 (en) * 2003-01-21 2013-06-11 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
AU2004312411B8 (en) * 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
US20080118487A1 (en) * 2004-09-30 2008-05-22 Orico Limited Myostatin Isoform
WO2006073827A2 (en) * 2004-12-30 2006-07-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
ES2533464T3 (es) * 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
AU2013231037B2 (en) * 2006-08-03 2016-05-12 Myostin Therapeutics Pty Ltd Myostatin antagonists
WO2008016314A1 (en) * 2006-08-03 2008-02-07 Orico Limited Myostatin antagonists
KR101123531B1 (ko) * 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TW201210612A (en) * 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
KR20140005864A (ko) 2010-08-16 2014-01-15 암젠 인코퍼레이티드 미오스타틴에 결합하는 항체, 조성물 및 방법
BR112013013354A2 (pt) 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente
SI2780368T1 (en) 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
HK1243940A1 (zh) * 2014-11-06 2018-07-27 Scholar Rock, Inc. 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
IL255010B2 (en) 2015-04-15 2024-01-01 Regeneron Pharma Methods of increasing strength and functionality with gdf8 inhibitors
SMT202500263T1 (it) * 2015-09-15 2025-09-12 Scholar Rock Inc Anticorpi anti-pro-miostatina/miostatina latente e loro usi
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20180094110A (ko) 2016-01-08 2018-08-22 스칼러 락, 인크. 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법
KR102271635B1 (ko) 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
DK3565592T5 (da) 2017-01-06 2024-09-02 Scholar Rock Inc Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
AU2019226551B2 (en) 2018-03-01 2025-02-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
TW202430247A (zh) 2022-12-22 2024-08-01 美商供石公司 肌肉生長抑制素活化之選擇性及強效抑制劑

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
WO1993008290A1 (en) 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
AU746643B2 (en) 1997-02-05 2002-05-02 Metamorphix International, Inc. Immunization against endogenous molecules
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US6368597B1 (en) * 1998-05-06 2002-04-09 Matamorphix, Inc. Methods of treating diabetes
US6284882B1 (en) 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
MXPA01013232A (es) * 1999-07-20 2005-05-24 Pharmexa As Metodo para identificar la actividad de gdf-8.
ZA200003786B (en) 1999-07-30 2002-01-21 Pfizer Prod Inc Myostatin regulatory region, nucleotide sequence determination and methods for its use.
WO2001026672A1 (en) 1999-10-13 2001-04-19 Roswell Park Memorial Institute Induction of a strong immune response to a self-tumor associated antigen
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
EP1572740A2 (en) 2002-12-11 2005-09-14 Pharmexa A/S Targeting single epitopes
EA009056B1 (ru) 2002-12-20 2007-10-26 Амген, Инк. Связывающие агенты, ингибирующие миостатин
AU2004312411B8 (en) * 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
US20060281075A1 (en) * 2004-12-22 2006-12-14 Large Scale Biology Corporation Purification of viruses, proteins and nucleic acids
WO2006073827A2 (en) 2004-12-30 2006-07-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine

Also Published As

Publication number Publication date
ECSP066683A (es) 2006-10-25
RU2006127314A (ru) 2008-02-10
US20050143306A1 (en) 2005-06-30
KR20060120229A (ko) 2006-11-24
JP2011083290A (ja) 2011-04-28
TWI357906B (en) 2012-02-11
US20090311282A1 (en) 2009-12-17
SG153874A1 (en) 2009-07-29
UA93855C2 (ru) 2011-03-25
CN1902221A (zh) 2007-01-24
US20080227156A1 (en) 2008-09-18
EP1699820A2 (en) 2006-09-13
NZ547593A (en) 2009-09-25
MXPA06007514A (es) 2006-08-31
BRPI0418317A (pt) 2007-05-02
ZA200605227B (en) 2007-03-28
AU2004312411A1 (en) 2005-07-21
PE20051050A1 (es) 2005-12-12
TW200526683A (en) 2005-08-16
AU2004312411B8 (en) 2011-11-24
RU2422460C2 (ru) 2011-06-27
WO2005066204A2 (en) 2005-07-21
NO20063478L (no) 2006-08-28
US7585648B2 (en) 2009-09-08
WO2005066204A3 (en) 2005-08-11
AU2004312411B2 (en) 2011-11-03
US7892561B2 (en) 2011-02-22
US7371726B2 (en) 2008-05-13
CA2551877A1 (en) 2005-07-21
IL176494A0 (en) 2006-10-05
JP2007535912A (ja) 2007-12-13

Similar Documents

Publication Publication Date Title
AR047345A1 (es) Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes
AR121383A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
MX2020001328A (es) Muteinas de interleucina 21 y metodos de tratamiento.
PE20210376A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
CY1109715T1 (el) IL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
DE69939747D1 (de) Verfahren von dna-impfung
EA200100425A1 (ru) Новые способы терапевтической вакцинации
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
CY1105282T1 (el) Διαγνωση της κοιλιοκακης με τη χρηση ενος επιτοπιου της γλιαδινης
PT2121731E (pt) Vacinas peptídicas para cancros que expressam antigénios associados a tumores
RU2017127024A (ru) Герпесвирус с измененным спектром мишеней, содержащий гибридный гликопротеин н
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
DE60131413D1 (de) Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie
PH12017502080A1 (en) Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
AR044603A1 (es) Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones
ATE435660T1 (de) Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
BR0303362A (pt) Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
WO2006102901A3 (en) Immunogenic egfr peptides comprising foreign t cell stimulating epitope
PE20010316A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS, PEPTIDOS Y PROTEINAS FlgE RELACIONADOS Y SUS USOS
MX2023013568A (es) Proteina sintetica para inducir inmunotolerancia.
PE20060860A1 (es) Vacuna basada en epitopes neutralizantes
DE602005019421D1 (de) Grosstechnisch geeigneter mikroorganismus
WO2004056316A8 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies

Legal Events

Date Code Title Description
FG Grant, registration